Moxifloxacin
Active ingredient · 2 therapeutic classes
Sold as VIGAMOX
- Drug class
- Fluoroquinolones
- Availability
- Prescription only
- Routes
- Intravenous, Oral, Ophthalmic
- Markets covered
- 3
- Products on record
- 37
- FDA reports (12 mo)
- 1,953
Overview
Plain-language summary, compiled from the cited regulatory records
Moxifloxacin is a fluoroquinolone antibacterial medication [1]. It is approved for treating infections in adults 18 years of age and older that are caused by specific susceptible bacteria [1].
Approved uses for moxifloxacin include community-acquired pneumonia, uncomplicated and complicated skin and skin structure infections, and complicated intra-abdominal infections [1]. It is also indicated for plague, acute bacterial sinusitis, and acute bacterial exacerbation of chronic bronchitis [1].
In the past 12 months, there have been 1953 adverse event reports associated with moxifloxacin [2]. The most frequently reported adverse events include pneumonia, drug hypersensitivity, asthma, vomiting, and dyspnoea [2]. Moxifloxacin is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 20 | November 18, 2025 |
| GB United Kingdom | MHRA | 12 | May 15, 2026 |
| US United States | FDA | 5 | March 17, 2026 |
CACanada· Health Canada
20 products
Uses
AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 6 WARNINGS AND PRECAUTIONS .........................................................................................
6 ADVERSE REACTIONS ......................................................................................................... 15 DRUG INTERACTIONS .........................................................................................................
19 DOSAGE AND ADMINISTRATION ..................................................................................... 21 OVERDOSAGE .......................................................................................................................
22 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 23 STORAGE AND STABILITY ................................................................................................. 31 SPECIAL HANDLING INSTRUCTIONS ...............................................................................
GBUnited Kingdom· MHRA
12 products
Uses
1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.
How to take
USUnited States· FDA
5 products
Uses
7 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin tablets and other antibacterial drugs. Moxifloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
3) ] . MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.
4) ]. 5) ]. 6) ] . 5 Plague Moxifloxacin tablets are indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients.
Efficacy studies of moxifloxacin could not be conducted in humans with plague for feasibility reasons. 7) ] . 1) ] . 14) ] and for some patients ABS is self-limiting, reserve moxifloxacin tablets for treatment of ABS in patients who have no alternative treatment options.
Drug interactions
Known interactions involving Moxifloxacin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 600. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02304821 · revised March 22, 2025
- [2]MHRA (UK) · PL252980272 · revised June 27, 2025
- [3]FDA DailyMed · 02c29e8e-8346-4e… · revised September 18, 2024 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.